Table of Contents
ISRN Public Health
Volume 2013, Article ID 298986, 6 pages
Research Article

Validation of a Chinese Version of the Self-Efficacy for Managing Chronic Disease 6-Item Scale in Patients with Hypertension in Primary Care

1Lab of Exercise Epidemiology, Graduate School of Sport Sciences, Waseda University, Mikajima, Saitama 3591192, Japan
2Institute of Chronic Diseases Control and Prevention, Beijing Center for Diseases Control and Prevention, Beijing 100013, China
3Lab of Exercise Epidemiology, Faculty of Sport Sciences, Waseda University, 2-579-15 Mikajima, Tokorozawa, Saitama 359-1192, Japan

Received 18 March 2013; Accepted 12 April 2013

Academic Editors: C. M. Buchalla, C. Rissel, A. Slep, and A. Zaborskis

Copyright © 2013 Huanhuan Hu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


The aim of this study was to validate a Chinese version of the Self-Efficacy for Managing Chronic Disease 6-Item Scale (SES6C). In 2012, a cross-sectional study was conducted in a community clinic, in Beijing, China. A total of 262 hypertension patients participated in this study. Concurrent validity was validated by Pearson’s correlations between the SES6C and Hospital Anxiety and Depression Scale (HADS). Intraclass correlation coefficients (ICC) were performed to evaluate test-retest reliability of the scale. Related factors of self-efficacy were explored in linear regression models. The results of our study display acceptable psychometric properties: the scale was two-dimensional, reproducible (ICC = 0.78; 95% CI, 0.70–0.84), and the reliability was good (Cronbach’s alpha = 0.88). Significant ( ; ) correlation was found between the level of self-efficacy and the level of psychological distress. In multivariable analysis, the factors significantly associated with self-efficacy were regular exercise ( , ), HADS total score ( , ) and health status ( , ). The study provides evidence that the SES6C is acceptable, valid and repeatable for hypertension patients.